[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Give thanks COVID safely", "description": "US Influenza\n\nUnited States\n\nDeaths, logged nearly 2,092\n\nHighest since 6th May, (2,611)\n\nRecord numbers of fatalities\n\nMaine, Alaska, Missouri, North Dakota, Indiana, Wisconsin, Washington, Ohio, Oregon \n\nDr. Fauci\n\nhttps://www.washingtonpost.com/politics/thanksgiving-covid-decisions/2020/11/24/1fa6aba4-2b72-11eb-8fa2-06e7cbb145c0_story.html\n\n\nWe had a great Thanksgiving last year and we\u2019re looking forward to a great Thanksgiving next year, but today we\u2019re going to call a timeout\n\nMarist poll\n\nhttp://maristpoll.marist.edu/marist-poll-results-analysis/#sthash.iGKNGTzM.PHNgfmUD.dpbs\n\n58% plan on celebrating Thanksgiving with fewer people\n\n36% plan same number of people as last year\n\n4% more people\n\nWho will have smaller gatherings\n\nDemocrats, 74%\n\nIndependents, 58%\n\nRepublicans, 39%\n\nMidwest, 65%\n\nNortheast, 63%\n\nWest, 57%\n\nSouth, 51%\n\nPersonal pandemic\n\n71% of adults know someone who has had coronavirus\n\nTravel\n\nhttps://www.washingtonpost.com/nation/2020/11/25/coronavirus-covid-live-updates-us/\n\nThanksgiving travel down?\n\nAAA estimates a 10% reduction in travel\n\n6.4 million doses in 24 hours\n\nhttps://www.washingtonpost.com/health/2020/11/24/vaccine-plan-first-doses/\n\nState allocation, which based overall population\n\n20 million people in 2020\n\nPfizer, larger centers first\n\nVaccine priorities?\n\nHealth-care workers\n\nResidents of long-term care facilities\n\nFirst responders\n\nTeachers\n\nGrocery workers\n\n100 million high-risk\n\n53 million adults over the age of 65\n\nUS Problems, next months\n\nWinter\n\nState, county, municipality\n\nCoordination, UK, US, Germany\n\nI woke up in a free country\n\nTesting accuracy, and may not be positive for days\n\nEveryone tested every 2 weeks\n\nContact tracing is weak, 100 people per infection need contacted\n\n100,000 contact tracers needed\n\nCompliance when pinged\n\nLack of therapeutics\n\nParticipation in clinical trials\n\nVaccine immunity delay, IgG could be several weeks\n\nAnti-vaccine thinking \n\nVitamin D denial\n\nUK Christmas\n\nhttps://www.bbc.co.uk/news/explainers-55056375\n\nBetween 23 and 27 December\n\nThree households, allowed to form a fixed temporary \"Christmas bubble\"\n\nMix indoors and stay overnight\n\nNorthern Ireland, 22 to 28 December\n\nEngland, existing support bubble counts as one household\n\nNo limit to the number of people in a household joining a bubble\n\nPeople self-isolating should not join a bubble\n\nAny positives or symptomatics within 48 hours, all have to self-isolate\n\nTravel restrictions will be lifted, visit families anywhere in the UK\n\nNo extra public transport\n\n\nScotland, relaxation of restrictions will not be extended to cover New Year's Eve\n\n\nCare home residents, not to join bubbles\n\n\nFrance\n\nEmmanuel Macron, restrictions remain in coming weeks\n\nContinue to stay at home\n\nTelecommute\n\nGive up private meetings and family gatherings\n\nAll nonessential travel\n\nChristmas Eve and New Year\u2019s Eve, share these moments together among family\n\nHalf dose of Oxford vaccine\n\nhttps://www.reuters.com/article/uk-health-coronavirus-astrazeneca-oxford/decades-of-work-and-half-a-dose-of-fortune-drove-oxford-vaccine-success-idUKKBN2832NG\n\nAdenovirus \u201cviral vector\u201d\n\nFlu, MERS and Ebola not yet at phase 3\n\nFatigue, headaches or arm aches were milder than expected\n\nHalf first dose\n\nSecond, full dose booster shot at the scheduled time\n\n90% verses 62%", "link": "https://www.youtube.com/watch?v=dt-RHHOMl2g", "date_published": "2020-11-25 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Australia Update", "description": "Life is essentially back to normal in Australia, Mr. David Davies reports from Australia\n\nAgUnity main link\nhttps://www.agunity.com\n\nAgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.", "link": "https://www.youtube.com/watch?v=L5DojKdL5dw", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Australia and the world", "description": "Mr David Davies highlights some essential principles for a sustainable future, illustrated through his AgUnity work.\n\nAgUnity is an Australian tech-for-good start-up empowering thousands of organizations working towards the UN Sustainable Development Goals to better connect with the last mile. By enabling trust, increasing transparency, giving access to market and limiting corruption through blockchain technology, AgUnity provides smallholder farmers a platform that is relevant and useful for them, essentially empowering them to lift themselves out of poverty. For more info, visit www.agunity.com or contact them via hello@agunity.com.\n\nAgUnity resources, https://agunity.sharepoint.com/sites/agunityexternalshare/Shared%20Documents/Forms/AllItems.aspx?id=%2Fsites%2Fagunityexternalshare%2FShared%20Documents%2F00%20AgUnity%20Media%20for%20External%20Parties%2F01%20Field%20Footage%20for%20Dr%20Campbell&p=true&originalPath=aHR0cHM6Ly9hZ3VuaXR5LnNoYXJlcG9pbnQuY29tLzpmOi9zL2FndW5pdHlleHRlcm5hbHNoYXJlL0VxVzlxMkRkT2ZaSmdBUVZEUDF0UUg0QnVvWlNJS0JFVU1hcnZZOF85VkVkcHc_cnRpbWU9TVJNeng2T1EyRWc", "link": "https://www.youtube.com/watch?v=eVTPtM6LzqU", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Oxford vaccine, looking very good", "description": "US Influenza\nOxford / AstraZeneca \n\nPhase 2 / 3\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext\n\n\n(23rd November)\n\nhttps://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html\n\nViral vector, weakened version, chimpanzee, common cold adenovirus\n\nAfter vaccination, the surface spike protein is produced\n\nAntibodies\n\nT cells\nInterim report, 131 confirmed infections\nPositive high-level results\n8,000 swabs per week\nTherefore picking up asymptomatics\nClinical trials of AZD1222\nUK and Brazil data only\nVaccine was highly effective in preventing COVID-19\nNo hospitalisations or severe cases of the disease were reported in participants receiving the vaccine\nGroup one, n = 2,741\nAZD1222 was given as a half dose\nFollowed by a full dose\nAt least one month apart\nVaccine efficacy of 90%\nGroup 2, n = 8,895\nTwo full doses at least one month apart\nVaccine efficacy 62 %\nCombined analysis from both dosing regimens, n = 11,636\nAn average efficacy of 70%\nAll results were statistically significant (p less than  = 0.0001)\nOne in 10,000\nMore data will continue to accumulate\nRefining the efficacy reading \nEstablishing the duration of protection.\nIndependent Data Safety Monitoring Board\nMet its primary endpoint\nProtection from COVID-19 occurring 14 days or more after receiving two doses\nNo serious safety events related to the vaccine have been confirmed\nAZD1222 was well tolerated across both dosing regimens\nAstraZeneca immediately prepare regulatory submission\nEarly approval\nEmergency Use Listing from the World Health Organization\nFor an accelerated pathway to low-income countries\nFull analysis of the interim results is being submitted for peer-reviewed journal\nProfessor Andrew Pollard\nThese  findings  show  that  we  have  an  effective  vaccine  that  will  save  many  lives\nExcitingly, we\u2019ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, \nmore people could be vaccinated with planned vaccine supply\nPascal Soriot, Chief Executive Officer\nSimple supply chain\nno-profit pledge\ncommitment to broad, equitable and timely access means\nit will be affordable and globally available\nsupplying hundreds of millions of doses on approval\nControl group\nMeningococcal conjugate vaccine called MenACWY\nor saline\nParticipants \nAged 18 years or over\nDiverse racial and geographic groups\nHealthy or have stable underlying medical conditions\nClinical trials are also being conducted in\nUS, Japan, Russia, South Africa, Kenya, Latin America\nPlanned trials in other European and Asian countries\nN = 60,000\nManufacturing capacity\n3 billion doses in 2021\nStorage / transport\n2-8 degrees Celsius\n36-46 degrees Fahrenheit\nFor at least six months\nAdministered within existing healthcare settings\nCOV002\nA single-blinded, multi-centre, randomised, controlled Phase II/III trial\nAssessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK\nAged 18 years or over\nHealthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus\nGroup one\nOne or two intramuscular doses of a half dose (~2.5 x1010 viral particles)\nComparator, meningococcal vaccine MenACWY.\nGroup two \nFull dose (~5x1010 viral particles)\nComparator, meningococcal vaccine MenACWY.\nClinical assessments for safety as well as immunogenicity\nMultiple timepoints\nFor a year\nWeekly swabbing for viral presence\nCOV003\nCOV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial in Brazil\nTwo intramuscular doses of a full dose (~5x1010 viral particles) of AZD1222 or comparator\nMeningococcal vaccine MenACWY as first dose and a saline placebo as second dose\nUK, Oxford / Astrazeneca \nThe UK has ordered 100m doses\nUS also\nUK government has supplied \u00a365.5m towards the development\nContracts with France, Germany, Italy and the Netherlands, up to 400 million doses\nSerum Institute of India, vaccine alliances, production for poorer countries, 1 billion doses\nChina, Brazil, Japan and Russia have also expressed interest.", "link": "https://www.youtube.com/watch?v=wAvnAkAMmmM", "date_published": "2020-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]